-
-
-
-
-
-
-
BofA Securities on Arcus Biosciences (RCUS): MRK Ph3 miss offers 'mixed' readthrough
-
-
-
-
-
-
-
Arcus presents kidney cancer drug data showing extended survival
-
-
-
-
-
-
-
Arcus Biosciences (RCUS) PT Lowered to $30 at Truist Securities
-
-
-
-
-
-
-
Arcus Biosciences (RCUS) PT Raised to $16 at BofA Securities
-
-
-
-
-
-
-
H.C. Wainwright Upgrades Arcus Biosciences (RCUS) to Buy
-
-
-
-
-
-
-
Arcus Biosciences (RCUS) Announces that Domvanalimab Plus Zimberelimab Improved Overall Survival in ARC-10
-
-
-
-
-
-
-
Arcus Biosciences (RCUS) PT Lowered to $23 at BofA Securities
-
434,704 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

